Hyperkalemia: a threat to RAAS inhibition?
Schrier
Robert W
RW
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D004347:Drug Interactions; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced* / Q000628:therapy; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013148:Spironolactone / Q000009:adverse effects
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone